Literature DB >> 15288408

Glyceryl trinitrate triggers premonitory symptoms in migraineurs.

S K Afridi1, H Kaube, P J Goadsby.   

Abstract

Studying attacks of migraine is considerably hampered by its fundamentally episodic nature. Developing approaches to triggering migraine reliably is important for advancing understanding of the disorder by facilitating its study. Based on the work of the Copenhagen Group we administered an intravenous infusion of 0.5 microg/kg/min glyceryl trinitrate (GTN) to 44 migraineurs, 23 migraine without aura, 21 migraine with aura, and to 12 healthy controls. We sought to characterise the GTN-induced migraine in terms of the clinical features of the attacks and reproducibility of triggering, and included a non-migraine control group for the purpose of comparing any effects to exclude an ordering effect. Of the 44 patients administered GTN, 33 had a migraine attack fulfilling International Headache Society criteria. Thirty-two attacks were of migraine without aura and one of migraine with aura. Twelve patients described typical premonitory symptoms, which have not been previously documented with GTN-induced migraine. A repeat attack was triggered in all subjects but one. In one case a visual aura was also triggered both times. Our study shows that GTN-induced triggering is common in our patients, and remarkably reproducible. The data will facilitate the use of the GTN model in studies requiring extensive planning, such as brain imaging, or where preventive questions are at issue. We also report the first patient with a reproducible GTN-triggered migraine with aura.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288408     DOI: 10.1016/j.pain.2004.05.007

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  36 in total

Review 1.  Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches.

Authors:  Peter J Goadsby
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 2.  Headache-type adverse effects of NO donors: vasodilation and beyond.

Authors:  G Bagdy; P Riba; V Kecskeméti; D Chase; G Juhász
Journal:  Br J Pharmacol       Date:  2010-03-19       Impact factor: 8.739

3.  Aura of mystery.

Authors:  Elie Dolgin
Journal:  Nat Med       Date:  2013-09       Impact factor: 53.440

4.  Triptan-induced enhancement of neuronal nitric oxide synthase in trigeminal ganglion dural afferents underlies increased responsiveness to potential migraine triggers.

Authors:  Milena De Felice; Michael H Ossipov; Ruizhong Wang; Gregory Dussor; Josephine Lai; Ian D Meng; Juliana Chichorro; John S Andrews; Suman Rakhit; Shawn Maddaford; David Dodick; Frank Porreca
Journal:  Brain       Date:  2010-07-13       Impact factor: 13.501

Review 5.  Nitric oxide-related drug targets in headache.

Authors:  Jes Olesen
Journal:  Neurotherapeutics       Date:  2010-04       Impact factor: 7.620

6.  New targets for migraine therapy.

Authors:  Amy R Tso; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2014-11       Impact factor: 3.598

7.  Psilocybin dose-dependently causes delayed, transient headaches in healthy volunteers.

Authors:  Matthew W Johnson; R Andrew Sewell; Roland R Griffiths
Journal:  Drug Alcohol Depend       Date:  2011-11-29       Impact factor: 4.492

Review 8.  Emerging targets in migraine.

Authors:  Jan Hoffmann; Peter J Goadsby
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 9.  Cerebral hemodynamics in the different phases of migraine and cluster headache.

Authors:  Jakob M Hansen; Christoph J Schankin
Journal:  J Cereb Blood Flow Metab       Date:  2017-08-31       Impact factor: 6.200

Review 10.  Peripheral nerve stimulation for the treatment of primary headache.

Authors:  Pyungbok Lee; Billy K Huh
Journal:  Curr Pain Headache Rep       Date:  2013-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.